Therapeutics of Parkinson's Disease and Other Movement Disorders
Hallett
€ 184.03
FREE Delivery in Ireland
Description for Therapeutics of Parkinson's Disease and Other Movement Disorders
Hardcover. * Comprehensive evidence-based overview of current therapies for PD and other movement disorders * Reviews basic neuropathology, mechanisms of neurodegeneration and principles of pharmacologic intervention. Editor(s): Hallet, Mark; Poewe, Werner. Num Pages: 512 pages, Illustrations. BIC Classification: MJN. Category: (P) Professional & Vocational. Dimension: 192 x 252 x 39. Weight in Grams: 1276.
- Provides a comprehensive update on therapies for Parkinson’s disease and other movement disorders
- Describes the basic mechanisms of neurodegeneration, pharmacologic interventions for motor and non-motor symptoms, and surgical management
- Features summary tables and algorithms that serve as a quick reference guide for practical treatment decisions
- The expert guidance of recognised authorities will enable readers of this book to plan their patients’ care with greater confidence
Product Details
Format
Hardback
Publication date
2008
Publisher
John Wiley and Sons Ltd United Kingdom
Number of pages
512
Condition
New
Number of Pages
528
Place of Publication
New York, United States
ISBN
9780470066485
SKU
V9780470066485
Shipping Time
Usually ships in 7 to 11 working days
Ref
99-50
About Hallett
Mark Hallett, MD, Senior Investigator at National Institute of Neurological Disorders and Stroke (NINDS), Chief of the Medical Neurology Branch and Chief of Human Motor Control Section; Editor-in-Chief of Clinical Neurophysiology; Associate Editor of Brain. Werner Poewe, Chairman of the Department of Neurology at Medical University of Innsbruck; Editorial board member of Movement Disorder, Journal of Neurology, Journal ... Read more
Reviews for Therapeutics of Parkinson's Disease and Other Movement Disorders
"This book can be strongly recommended and is an asset to libraries of both movement disorder specialists and general neurologists. Its logical structure, linking therapy with underlying pathophysiology, means that it will remain a useful reference even as new therapies inevitably emerge." (The Lancet Neurology, July 2009)